160 related articles for article (PubMed ID: 37985959)
1. Unveiling the immunogenomic landscape of cholangiocarcinoma: Identifying new prognostic markers and therapeutic targets based on CCL5 expression.
Wang J; Xiang D; Dai Z; Zhu J; Du Y; Fu G; Chu X
J Gene Med; 2024 Jan; 26(1):e3630. PubMed ID: 37985959
[TBL] [Abstract][Full Text] [Related]
2. Identification and validation of a novel ferroptosis-related gene signature for prognosis and potential therapeutic target prediction in cholangiocarcinoma.
Sae-Fung A; Mutirangura A; Jitkaew S
Front Immunol; 2022; 13():1051273. PubMed ID: 36733386
[TBL] [Abstract][Full Text] [Related]
3. Integrated pan-cancer analysis of centromere protein F and experimental verification of its role and clinical significance in cholangiocarcinoma.
Cao Z; Zeng L; Wang Z; Wen X; Zhang J
Funct Integr Genomics; 2023 May; 23(2):190. PubMed ID: 37247093
[TBL] [Abstract][Full Text] [Related]
4. Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review).
Yang S; Zou R; Dai Y; Hu Y; Li F; Hu H
Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37888583
[TBL] [Abstract][Full Text] [Related]
5. Tertiary lymphoid structures predict the prognosis and immunotherapy response of cholangiocarcinoma.
Shang T; Jiang T; Lu T; Wang H; Cui X; Pan Y; Xu M; Pei M; Ding Z; Feng X; Lin Y; Li X; Tan Y; Feng F; Dong H; Wang H; Dong L
Front Immunol; 2023; 14():1166497. PubMed ID: 37234171
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.
Zhang R; Li Q; Fu J; Jin Z; Su J; Zhang J; Chen C; Geng Z; Zhang D
BMC Cancer; 2021 Feb; 21(1):112. PubMed ID: 33535978
[TBL] [Abstract][Full Text] [Related]
7. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.
Churi CR; Shroff R; Wang Y; Rashid A; Kang HC; Weatherly J; Zuo M; Zinner R; Hong D; Meric-Bernstam F; Janku F; Crane CH; Mishra L; Vauthey JN; Wolff RA; Mills G; Javle M
PLoS One; 2014; 9(12):e115383. PubMed ID: 25536104
[TBL] [Abstract][Full Text] [Related]
8. Cholangiocarcinoma - novel biological insights and therapeutic strategies.
Ilyas SI; Affo S; Goyal L; Lamarca A; Sapisochin G; Yang JD; Gores GJ
Nat Rev Clin Oncol; 2023 Jul; 20(7):470-486. PubMed ID: 37188899
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker.
Utispan K; Thuwajit P; Abiko Y; Charngkaew K; Paupairoj A; Chau-in S; Thuwajit C
Mol Cancer; 2010 Jan; 9():13. PubMed ID: 20096135
[TBL] [Abstract][Full Text] [Related]
10. Multimodule characterization of immune subgroups in intrahepatic cholangiocarcinoma reveals distinct therapeutic vulnerabilities.
Lin J; Dai Y; Sang C; Song G; Xiang B; Zhang M; Dong L; Xia X; Ma J; Shen X; Ji S; Zhang S; Wang M; Fang H; Zhang X; Wang X; Zhang B; Zhou J; Fan J; Zhou H; Gao D; Gao Q
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35863823
[TBL] [Abstract][Full Text] [Related]
11. Targeting cholangiocarcinoma.
Mertens JC; Ilyas SI; Gores GJ
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1454-1460. PubMed ID: 28844952
[TBL] [Abstract][Full Text] [Related]
12. Proteogenomic characterization of cholangiocarcinoma.
Deng M; Ran P; Chen L; Wang Y; Yu Z; Cai K; Feng J; Qin Z; Yin Y; Tan S; Liu Y; Xu C; Shi G; Ji Y; Zhao JY; Zhou J; Fan J; Hou Y; Ding C
Hepatology; 2023 Feb; 77(2):411-429. PubMed ID: 35716043
[TBL] [Abstract][Full Text] [Related]
13. Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures.
Mody K; Jain P; El-Refai SM; Azad NS; Zabransky DJ; Baretti M; Shroff RT; Kelley RK; El-Khouiery AB; Hockenberry AJ; Lau D; Lesinski GB; Yarchoan M
JCO Precis Oncol; 2022 Jun; 6():e2100510. PubMed ID: 35675577
[TBL] [Abstract][Full Text] [Related]
14. The Prognostic Role of SOCS3 and A20 in Human Cholangiocarcinoma.
Wang Y; Wan M; Zhou Q; Wang H; Wang Z; Zhong X; Zhang L; Tai S; Cui Y
PLoS One; 2015; 10(10):e0141165. PubMed ID: 26485275
[TBL] [Abstract][Full Text] [Related]
15. The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine.
Rimassa L; Personeni N; Aghemo A; Lleo A
J Autoimmun; 2019 Jun; 100():17-26. PubMed ID: 30862450
[TBL] [Abstract][Full Text] [Related]
16. Identification of Novel Cuproptosis-Related Genes Mediating the Prognosis and Immune Microenvironment in Cholangiocarcinoma.
Liu Q; Zhu J; Huang Z; Zhang X; Yang J
Technol Cancer Res Treat; 2024; 23():15330338241239139. PubMed ID: 38613350
[TBL] [Abstract][Full Text] [Related]
17. Macrophages-aPKC
Yang T; Deng Z; Xu L; Li X; Yang T; Qian Y; Lu Y; Tian L; Yao W; Wang J
J Exp Clin Cancer Res; 2022 Jan; 41(1):23. PubMed ID: 35033156
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of microRNA-203 in cholangiocarcinoma.
Li J; Gao B; Huang Z; Duan T; Li D; Zhang S; Zhao Y; Liu L; Wang Q; Chen Z; Cheng K
Int J Clin Exp Pathol; 2015; 8(8):9512-6. PubMed ID: 26464713
[TBL] [Abstract][Full Text] [Related]
19. Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies.
Cao H; Huang T; Dai M; Kong X; Liu H; Zheng Z; Sun G; Sun G; Rong D; Jin Z; Tang W; Xia Y
Int J Biol Sci; 2022; 18(14):5369-5390. PubMed ID: 36147461
[TBL] [Abstract][Full Text] [Related]
20. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma.
Montal R; Sia D; Montironi C; Leow WQ; Esteban-Fabró R; Pinyol R; Torres-Martin M; Bassaganyas L; Moeini A; Peix J; Cabellos L; Maeda M; Villacorta-Martin C; Tabrizian P; Rodriguez-Carunchio L; Castellano G; Sempoux C; Minguez B; Pawlik TM; Labgaa I; Roberts LR; Sole M; Fiel MI; Thung S; Fuster J; Roayaie S; Villanueva A; Schwartz M; Llovet JM
J Hepatol; 2020 Aug; 73(2):315-327. PubMed ID: 32173382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
